886547-94-0

Usage

Uses

Used in Organic Chemistry Research:
1-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-boronic acid pinacol ester is used as a reagent in organic chemistry for the synthesis of complex organic compounds. Its boronic ester functionality allows for catalytic or stoichiometric processes in the formation of new molecular structures.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-boronic acid pinacol ester is utilized as a building block for the development of pharmaceutical agents. Its pyrrolopyridine core, known for its biological significance, is employed in creating novel molecular architectures with potential therapeutic applications.
Used in Drug Design and Synthesis:
1-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-boronic acid pinacol ester is used as a key intermediate in drug design and synthesis. Its unique structure and reactivity contribute to the development of new pharmaceutical agents with improved efficacy and selectivity.
Used in Advanced Material Synthesis:
1-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-boronic acid pinacol ester is also used in the synthesis of advanced materials, such as organic semiconductors and optoelectronic devices, due to its pyrrolopyridine core and boronic ester functionality, which can be tailored for specific material properties.

InChI:InChI=1S/C19H27BN2O4/c1-12-14-11-13(20-25-18(5,6)19(7,8)26-20)9-10-15(14)22(21-12)16(23)24-17(2,3)4/h9-11H,1-8H3

Upstream product

• 887115-53-9 3-iodo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 98-09-9 benzenesulfonyl chloride 
• 74420-15-8 3-bromo-1H-pyrrolo[2,3-b]pyridine 
• 271-63-6 7-Azaindole 
• 143141-23-5 1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridine 
• 880769-95-9 3-bromo-1-(benzenesulfonyl)-1H-pyrrolo [2,3-b]pyridine 

Downstream Products

• 886547-96-2 3-(2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1339174-87-6 4-[7-(1-Benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-oxo-3,4-dihydro-phthalazin-1-ylmethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1339174-89-8 6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(piperidin-4-ylmethyl)phthalazin-1(2H)-one 
• 1365534-14-0 C₁₈H₂₀N₄O 
• 1365534-22-0 C₂₈H₄₂N₄O₂Si 
• 1365534-23-1 C₂₂H₂₈N₄O 
• 1365534-25-3 C₂₀H₂₄N₄O 
• 1365534-16-2 C₁₈H₂₀N₄O 
• 1365534-27-5 C₁₉H₂₂N₄O 
• 1365534-18-4 C₁₇H₂₀N₆O 
• 1365534-19-5 C₁₈H₁₃ClN₄O₃S 
• 1001413-72-4 C₁₈H₁₁N₅O₂S 
• 1262293-76-4 N-cyclohexyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine 
• 1262293-86-6 6-(cyclohexylamino)-4-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)picolinonitrile 

Relevant academic research and scientific papers

Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors

Inhibitors of the Hippo signaling pathway have been demonstrated to have a potential clinical application in cases such as tissue repair and organ regeneration. However, there is a lack of potent Hippo pathway inhibitors at present. Herein we report the discovery of a series of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo pathway inhibitors by utilizing a cell line-based screening model (A549-CTGF). Structure-activity relationship (SAR) of these compounds was also discussed. The most potent compound in the A549-CTGF cell assay, 11g, was then evaluated by real-time PCR and immunofluorescence assays. Overall, this study provides a starting point for later drug discovery targeting the Hippo signaling pathway.

PYRROLOPYRIDINE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing sa

PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, Y, Z, n, and m are defined in the description. The present invention relates also to compositions cont

PYRROLOPYRAZINONE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, Y, Z, n, and m are defined in the description. The present invention relates also to compositions cont

PYRIDINONYL PDK1 INHIBITORS

The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.

INHIBITORS OF Akt ACTIVITY

Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors

A novel series of 2-amino-4-(7-azaindol-3-yl)pyrimidines was discovered as cyclin dependent kinase 1 (CDK1) inhibitors. The core structure was synthesized via Pd(II) catalyzed coupling reaction. A number of analogues showed good potency for CDK1 and exhib

PYRIMIDINYL SUBSTITUTED FUSED-PYRROLYL COMPOUNDS USEFUL IN TREATING KINASE DISORDERS

The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.